Learn About Adult T-Cell Leukemia

What is the definition of Adult T-Cell Leukemia?
Adult T-cell leukemia/lymphoma (ATL) is is a rare and aggressive T-cell lymphoma that is linked to infection by the human T-cell lymphotropic virus 1 (HTLV-1). The exact mechanism by which HTLV-I infection causes the ATL is unknown. The clinical features of ATL include generalized swelling of the lymph nodes (lymphadenopathy), increased liver and spleen size (hepatosplenomegaly), immunosuppression, high levels of calcium in the blood, lytic bone lesions (spots that appear as 'holes' on a standard bone x-ray), and skin lesions. There are four basic clinical variants of ATL: acute (60% of cases), lymphomatous (20 % of cases), chronic (10% of cases) and smoldering (10% of cases).
Save information for later
Sign Up
What are the alternative names for Adult T-Cell Leukemia?
  • Adult T-cell leukemia/lymphoma
  • ATLL
  • Adult T-cell leukaemia
  • Adult T-cell leukaemia/lymphoma (HTLV-1 positive)
  • Adult T-cell lymphoma
Who are the top Adult T-Cell Leukemia Local Doctors?
TK
Dr. Tapan M. Kadia
Oncology | Hematology Oncology | Hematology
Elite
Highly rated in
32
conditions
Oncology
Hematology Oncology
Hematology

University of Texas System

Physicians Referral Service

1515 Holcombe Blvd 
Houston, TX 77030

Tapan Kadia is an Oncologist and a Hematologist Oncology doctor in Houston, Texas. Dr. Kadia has been practicing medicine for over 21 years and is rated as an Elite doctor by MediFind in the treatment of Adult T-Cell Leukemia. He is also highly rated in 32 other conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia, Myelodysplastic Syndrome MDS, Leukemia, and Acute Myeloblastic Leukemia with Maturation. He is licensed to treat patients in Texas. Dr. Kadia is currently accepting new patients.

View Profile
TL
Dr. Thomas P. Loughran
Oncology | Hematology Oncology | Hematology
Elite
Highly rated in
13
conditions
Oncology
Hematology Oncology
Hematology

UVA Health System

Emily Couric Clinical Cancer Center

1240 Lee St 
Charlottesville, VA 22908

Thomas Loughran is an Oncologist and a Hematologist Oncology doctor in Charlottesville, Virginia. Dr. Loughran has been practicing medicine for over 43 years and is rated as an Elite doctor by MediFind in the treatment of Adult T-Cell Leukemia. He is also highly rated in 13 other conditions, according to our data. His top areas of expertise are Adult T-Cell Leukemia, Felty Syndrome, Leukemia, and Chronic T-Cell Leukemia. He is licensed to treat patients in Pennsylvania and Virginia. Dr. Loughran is currently accepting new patients.

View Profile
 
 
 
 
Learn about our expert tiers
Learn more
EJ
Elias J. Jabbour
Dr. Elias J. Jabbour
Hematology Oncology
Elite
Highly rated in
37
conditions
Hematology Oncology

University of Texas System

Physicians Referral Service

1515 Holcombe Blvd 
Houston, TX 77030

Elias Jabbour is a Hematologist Oncology doctor in Houston, Texas. Dr. Jabbour has been practicing medicine for over 24 years and is rated as an Elite doctor by MediFind in the treatment of Adult T-Cell Leukemia. He is also highly rated in 37 other conditions, according to our data. His top areas of expertise are Acute Lymphoblastic Leukemia ALL, Acute Myeloid Leukemia, Leukemia, and Myelodysplastic Syndrome MDS. He is licensed to treat patients in Texas. Dr. Jabbour is currently accepting new patients.

View Profile
View All Doctors
What are the latest Adult T-Cell Leukemia Clinical Trials?
Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-05: A Phase 1 Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia
Who is this study for: Patients up to 30 years with CD19+22+ leukemia
Status: Recruiting
Start Date: November 3, 2017
Intervention Type: Biological
Phase: Phase 1
View Trial
Summary: Patients with relapsed or refractory leukemia often develop resistance to chemotherapy and some patients who relapse following CD19 directed therapy relapse with CD19 negative leukemia. For this reason, the investigators are attempting to use T-cells obtained directly from the patient, which can be genetically modified to express two chimeric antigen receptors (CARs). One is to recognize CD19 and ...
Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 1, Open-Label, Multicenter Study of HMPL-306 in Advanced Hematological Malignancies With Isocitrate Dehydrogenase (IDH) Mutations
Who is this study for: Patients with advanced hematological malignancies with isocitrate dehydrogenase mutations
Status: Recruiting
Start Date: February 28, 2021
Intervention Type: Drug
Phase: Phase 1
View Trial
Summary: An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in subjects with advanced relapsed, refractory, or resistant hematological malignancies that harbor IDH mutations.
View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center

What are the Latest Advances for Adult T-Cell Leukemia?
Large granular lymphocytic leukemia cured by allogeneic stem cell transplant: a case report.
Condition: Large Granular Lymphocytic Leukemia
Journal: Journal of medical case reports
Treatment Used: Allogeneic Stem Cell Transplant
Number of Patients: 1
Published: June 07, 2022
View publication
Summary: Large granular lymphocytic leukemia cured by allogeneic stem cell transplant: a case report.
HLA-haploidentical peripheral blood stem cell transplantation with post-transplantation cyclophosphamide for adult T-cell leukemia.
Condition: Adult T-Cell Leukemia (ATL)
Journal: The Japanese journal of clinical hematology
Treatment Used: HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide
Published: June 06, 2022
View publication
Summary: HLA-haploidentical peripheral blood stem cell transplantation with post-transplantation cyclophosphamide for adult T-cell leukemia.
Tired of the same old research?
Check Latest Advances
Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma.
Condition: Peripheral T-Cell Lymphoma (PTCL)
Journal: Leukemia
Treatment Used: Guadecitabine
Number of Patients: 20
Published: April 23, 2022
View publication
Summary: Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma.
View All Latest Advances